Daily Focus: HMG (Human Menopausal Gonadotropin) — A Decades-Old Fertility Workhorse Back in the Trial Spotlight
Two newly registered randomized trials, including a large Phase 3 study, are re-examining whether the LH activity in human menopausal gonadotropin improves live-birth and embryo-quality outcomes in IVF.
Source: ClinicalTrials.gov — GRACE hMG Phase 3 Trial
Amycretin Heads Into Late-Stage Testing as Novo Bets on a Single Amylin/GLP-1 Peptide
Novo Nordisk is advancing injectable and oral amycretin, one peptide that activates both GLP-1 and amylin receptors, into Phase 3 programs for obesity and type 2 diabetes.
Source: Fierce Biotech — Amycretin Phase 3 Plans
Icotrokinra Shows Oral Peptides Can Compete With Injectable Biologics in Psoriasis
Johnson & Johnson's IL-23 receptor-blocking oral peptide Icotyde, approved this spring, is emerging as a template for pill-form alternatives to antibody therapies.
Source: Healio — Icotrokinra FDA Approval
CagriSema Awaits FDA Verdict as Q4 2026 Decision Window Opens
Novo Nordisk's cagrilintide-semaglutide combination is expected to get an FDA decision before year-end, though a missed head-to-head goal against tirzepatide hangs over its prospects.
Source: Drugs.com — CagriSema Approval Status
Enlicitide Becomes First Oral PCSK9 Inhibitor, a Win for Macrocyclic Peptide Design
Merck's enlicitide (Lipfendra), a once-daily macrocyclic peptide tablet, is FDA-approved for lowering LDL cholesterol, showing engineered peptides can reach targets once reserved for injectable antibodies.
Source: TCTMD — Enlicitide FDA Approval
Peptide Drug Summit Opens in Munich With Focus on Delivery and Oral Bioavailability
The two-day Peptide Drug Summit begins today in Munich, gathering developers to tackle the stability and delivery hurdles that still limit many peptide therapeutics.
Source: BioM — Peptide Drug Summit 2026
Independent Replication Supports Epitalon's Telomerase Activation in Human Cell Models
A 2025 Biogerontology study replicated the central laboratory finding that the AEDG tetrapeptide extends telomere length in cultured human cells, keeping Epitalon on the longevity research map even as clinical evidence lags.
Source: Yahoo Finance Healthcare
BPC-157 Clinical Evidence Base Remains Thin Despite Advisory Vote and Growing Patient Use
An FDA scientific review of BPC-157 found that only five human trials existed, all short in duration and small in sample size, highlighting a widening gap between booming consumer demand and genuine clinical data.
Source: PMC — Pharmaceuticals Commentary 2026
Half-Million-Patient Cohort Flags Vestibular Disorder Signal With Semaglutide and Tirzepatide
A real-world analysis of nearly 500,000 adults prescribed GLP-1 or GLP-1/GIP therapy identified an association between incretin use and vestibular disorders, adding a new safety consideration beyond the familiar GI profile.
Source: PMC — Vestibular Disorders Cohort Study
FDA Advisory Panel Backs Six Peptides for Compounding — But Final Rulemaking Still Pending
The Pharmacy Compounding Advisory Committee's July 2026 recommendation for BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax moves the needle, but pharmacies still cannot legally compound these peptides until FDA formally amends the 503A Bulks List.
Source: AJMC
Retatrutide TRIUMPH-1 Phase 3 Reports Average 30% Weight Loss at 104 Weeks
Eli Lilly's triple-agonist retatrutide produced an average 30.3% body-weight reduction at the 12 mg dose in the 2,339-participant TRIUMPH-1 obesity trial, setting a new benchmark for incretin therapy.
Source: AJMC
Daily Focus: HGH Fragment 176-191 — The Lipolytic Tail With Beta-3 Receptor Dependence
Fresh 2026 reviews of HGH Fragment 176-191 confirm its direct lipolytic action on adipocytes but highlight the stark divide between preclinical fat-loss data and the near-total absence of human trial evidence.
Source: HGH Fragment 176-191 Research Overview
Medicare to Launch GLP-1 Coverage Demonstration Program in July 2026
CMS announces a new payment demonstration that will provide Medicare beneficiaries with access to GLP-1 medications for obesity, bridging to the full BALANCE Model in 2027.
Source: CMS.gov
GLP-1 Drugs Show Promise for Addiction Treatment in Emerging Research
Harvard researchers outline expanding clinical applications for GLP-1 peptides beyond weight loss, including early evidence of reduced cravings in substance use disorders.
Source: Harvard Gazette
Mitochondrial Peptides Emerge as Major Research Category in 2026
MOTS-C and humanin are moving from niche curiosities to recognized research targets, with new studies exploring their roles in aging, metabolism, and exercise mimicry.
Source: Alpha Peptides
Novartis Wins Expanded FDA Approval for Peptide-Based Prostate Cancer Therapy Pluvicto
Pluvicto (lutetium-177 vipivotide tetraxetan) receives expanded approval for use before chemotherapy in metastatic prostate cancer, showing a 28% reduction in disease progression risk.
Source: Peptide Protocol Wiki
Global Peptide Synthesis Market Hits $1.9 Billion as Demand Surges
A new industry report shows the global research peptide market has reached $1.9 billion in 2026, driven by therapeutic demand and projected to hit $2.59 billion by 2031.
Source: GlobeNewsWire
Genetic Study Reveals 10% of Population May Be Resistant to GLP-1 Diabetes Drugs
Stanford researchers have identified genetic variants carried by roughly one in ten people that significantly reduce the effectiveness of GLP-1 receptor agonists for blood sugar control.
Source: Stanford Medicine
Eli Lilly's Retatrutide Delivers Record 71-Pound Average Weight Loss in Phase 3 Trial
The triple-agonist peptide retatrutide achieved unprecedented weight loss in the TRIUMPH-4 trial while also providing substantial relief from osteoarthritis knee pain.
Source: Eli Lilly Investor Relations
14 Peptides Including BPC-157 and TB-500 Reclassified Back to Legal Compounding Status
HHS Secretary Kennedy announces that 14 previously restricted peptides will return to Category 1, restoring access through compounding pharmacies with a prescription.
Source: Peptibase
FDA Approves Foundayo (Orforglipron) — First Daily Oral GLP-1 Pill for Weight Loss
Eli Lilly's Foundayo becomes the first once-daily oral GLP-1 receptor agonist approved by the FDA, eliminating the need for injections in obesity treatment.
Source: Medical News Today
Stanford Researchers Discover BRP Peptide — A Potential Side-Effect-Free Alternative to Ozempic
Stanford scientists have identified a novel brain-targeted peptide called BRP that suppresses appetite as effectively as GLP-1 drugs but without nausea or muscle loss in animal models.
Source: ScienceDaily
Daily Briefing
Get the latest peptide research delivered to your inbox every morning.
The Peptide Wizard
High-quality research peptides for lab use. Third-party tested with certificate of analysis available on every product.
Visit The Peptide WizardSponsored content. ThePBrief receives compensation. For research purposes only.